Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CurePML in Progressive Multifocal Leukoencephalopathy
NCT06990087Phase 2Recruiting
- Sponsor
- Hannover Medical School
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ALVR107 in progressive multifocal leukoencephalopathy (PML), sponsored by Hannover Medical School. Primary endpoint: Efficacy of treatment at 6 months. Started Feb 2026; status: recruiting.
02
Drugs
ALVR107
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT06990087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990087.